title: Design control considerations for biologic-device combination products.
abstract: Combination products are therapeutic and diagnostic medical products that combine drugs, devices, and/or biological products with one another. Historically, biologics development involved identifying efficacious doses administered to patients intravenously or perhaps by a syringe. Until fairly recently, there has been limited focus on developing an accompanying medical device, such as a prefilled syringe or auto-injector, to enable easy and more efficient delivery. For the last several years, and looking forward, where there may be little to distinguish biologics medicines with relatively similar efficacy profiles, the biotechnology market is beginning to differentiate products by patient-focused, biologic-device based combination products. As innovative as biologic-device combination products are, they can pose considerable development, regulatory, and commercialization challenges due to unique physicochemical properties and special clinical considerations (e.g., dosing volumes, frequency, co-medications, etc.) of the biologic medicine. A biologic-device combination product is a marriage between two partners with "cultural differences," so to speak. There are clear differences in the development, review, and commercialization processes of the biologic and the device. When these two cultures come together in a combination product, developers and reviewers must find ways to address the design controls and risk management processes of both the biologic and device, and knit them into a single entity with supporting product approval documentation. Moreover, digital medicine and connected health trends are pushing the boundaries of combination product development and regulations even further. Despite an admirable cooperation between industry and FDA in recent years, unique product configurations and design features have resulted in review challenges. These challenges have prompted agency reviewers to modernize consultation processes, while at the same time, promoting development of innovative, safe and effective combination products. It remains the manufacturer's responsibility to comply with the relevant requirements and regulations, and develop good business practices that clearly describe how these practices comply with FDA's final rule (21 CFR Part 4) and aligns with the company's already established quality system.
authors.affiliation: AstraZeneca/MedImmune, One MedImmune Way, Gaithersburg, MD 20878, United States.
authors.forename: Dave
authors.initials: D
authors.lastname: Anderson
authors.affiliation: AstraZeneca/MedImmune, One MedImmune Way, Gaithersburg, MD 20878, United States.
authors.forename: Roger
authors.initials: R
authors.lastname: Liu
authors.affiliation: AstraZeneca/MedImmune, One MedImmune Way, Gaithersburg, MD 20878, United States.
authors.forename: J
authors.initials: J
authors.lastname: Anand Subramony
authors.affiliation: AstraZeneca/MedImmune, One MedImmune Way, Gaithersburg, MD 20878, United States. Electronic address: cammackj@medimmune.com.
authors.forename: Jon
authors.initials: J
authors.lastname: Cammack
mesh_terms: D000818:Animals; D001688:Biological Products / Q000008:administration & dosage*; D004867:Equipment Design; D004864:Equipment and Supplies; D006801:Humans; D004364:Pharmaceutical Preparations / Q000008:administration & dosage*; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence
chemical_list: D001688:Biological Products; D004364:Pharmaceutical Preparations
keywords: Biologics; CGMP; Combination products; Design controls; FDA; Medical device; Quality systems